5-Hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin

Medical Hypotheses

Volumn 65, Issue 1, 2005, Pages 138-144

  Turner, Erick H ^a,b,c   Blackwell, Aaron D ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CLOMIPRAMINE; DECARBOXYLASE INHIBITOR; FLUOXETINE; INTERFERON; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN;

ANXIETY; ARTICLE; CANCER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; COMMERCIAL PHENOMENA; CONFUSION; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA MYALGIA SYNDROME; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEPATITIS C; HUMAN; INSOMNIA; LETHARGY; MEMORY DISORDER; META ANALYSIS; MOOD DISORDER; NAUSEA; NONHUMAN; OCCUPATIONAL HEALTH; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONIN SYNDROME; SIDE EFFECT; SOCIAL INTERACTION; SUICIDE ATTEMPT; SYNAPSE; VIRUS INFECTION; VOMITING;

5-HYDROXYTRYPTOPHAN; ANTIVIRAL AGENTS; BRAIN CHEMISTRY; DEPRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MODELS, BIOLOGICAL; RISK FACTORS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPSES;

HEPATITIS C VIRUS;

EID: 18944402421     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.01.026     Document Type: Article

References (55)

1. M.J. Alter, D. Kruszon-Moran, and O.V. Nainan The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
2. Seiden C. An MM&M corporate profile: DTC Catapults schering into top rank of growth companies, 〈www.cpsnet.com/reprints/1999/12/Schering. pdf〉; 1999 [accessed 15:12:04]
3. W.R. Yates, and O. Gleason Hepatitis C and depression Depress Anxiety 7 1998 188 193
4. Physicians desk reference. Montvale (NJ): Medical Economics Company, Inc.; 2003
5. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Washington: American Psychiatric Association; 1994
6. A. Yokoyama, Y. Kimura, and J. Shigemura Psychiatric side effects of interferon J Toxicol Sci 21 1996 93 96
7. P. Hauser, J. Khosla, and H. Aurora A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C Mol Psychiat 7 2002 942 947
8. H. Miyaoka, T. Otsubo, K. Kamijima, M. Ishii, M. Onuki, and K. Mitamura Depression from interferon therapy in patients with hepatitis C Am J Psychiat 156 1999 1120
9. D. Musselman, D. Lawson, and J. Gumnick Paroxetine for the prevention of depression induced by high-dose interferon alfa N Engl J Med 344 2001 961 966
10. M. Malaguarnera, I. Di Fazio, and S. Restuccia Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha Neuropsychobiology 37 1998 93 97
11. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease; 1998
12. R.D. Porsolt, M. Le Pichon, and M. Jalfre Depression: a new animal model sensitive to antidepressant treatments Nature 266 1977 730 732
13. M. Makino, Y. Kitano, C. Komiyama, and K. Takasuna Human interferon-alpha increases immobility in the forced swimming test in rats Psychopharmacology (Berl) 148 2000 106 110
14. J. Levenson, and H. Fallon Fluoxetine treatment of depression caused by interferon-alpha Am J Gastroenterol 88 1993 760 761
15. T. Schramm, B. Lawford, G. Macdonald, and W. Cooksley Sertraline treatment of interferon-alfa-induced depressive disorder Med J Aust 173 2000 359 361
16. D.C. Steffens, K.R. Krishnan, and M.J. Helms Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis Depress Anxiety 6 1997 10 18
17. O. Morikawa, N. Sakai, H. Obara, and N. Saito Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter Eur J Pharmacol 349 1998 317 324
18. H. Wolf Studies on tryptophan metabolism in man Scand J Clin Lab Invest Suppl 136 1974 1 186
19. D.B. Menkes, and J.A. MacDonald Interferons, serotonin and neurotoxicity Psychol Med 30 2000 259 268
20. S. Curreli, F. Romerio, P. Mirandola, P. Barion, K. Bemis, and D. Zella Human primary CD4 + T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase J Interferon Cytokine Res 21 2001 431 437
21. T.L. Sweeten, M. Ferris, C.J. McDougle, P. Kwo, and M.W. Taylor Induction of indoleamine 2,3-dioxygenase in vivo by IFN-con1 J Interferon Cytokine Res 21 2001 631 633
22. S. Bonaccorso, V. Marino, and A. Puzella Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system J Clin Psychopharmacol 22 2002 86 90
23. A. Kamiya, N. Kojima, T. Kinoshita, Y. Sakai, and A. Miyaijma Maturation of fetal hepatocytes in vitro by extracellular matrices and oncostatin M: induction of tryptophan oxygenase Hepatology 35 2002 1351 1359
24. P.L. Delgado, D.S. Charney, L.H. Price, G.K. Aghajanian, H. Landis, and G.R. Heninger Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan Arch Gen Psychiatry 47 1990 411 418
25. R.W. Lam, A.P. Zis, A. Grewal, P.L. Delgado, D.S. Charney, and J.H. Krystal Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy Arch Gen Psychiatry 53 1996 41 44
26. A. Neumeister, E.H. Turner, and J.R. Matthews Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy Arch Gen Psychiatry 55 1998 524 530
27. L. Capuron, A. Ravaud, P.J. Neveu, A.H. Miller, M. Maes, and R. Dantzer Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy Mol Psychiat 7 2002 468 473
28. H. Rang, M. Dale, J. Ritter, and P. Moore Pharmacology 5th ed. 2003 Churchill Livingstone Edinburgh
29. S.A. Smith, F.P. Carr, and C.I. Pogson The metabolism of l-tryptophan by isolated rat liver cells. Quantification of the relative importance of, and the effect of nutritional status on, the individual pathways of tryptophan metabolism Biochem J 192 Nov 15 1980 673 686
30. I. Magnussen, and F. Nielsen-Kudsk Bioavailability and related pharmacokinetics in man of orally administered l-5-hydroxytryptophan in steady state Acta Pharmacol Toxicol (Copenh) 46 1980 257 262
31. I. Magnussen, T.S. Jensen, J.H. Rand, and M.H. Van Woert Plasma accumulation of metabolism of orally administered single dose l-5-hydroxytryptophan in man Acta Pharmacol Toxicol (Copenh) 49 1981 184 189
32. T.C. Birdsall 5-Hydroxytryptophan: a clinically-effective serotonin precursor Altern Med Rev 3 1998 271 280
33. P.E. Penn, W.J. McBride, J.N. Hingtgen, and M.H. Aprison Differential uptake, metabolism and behavioral effects of the d and l isomers of 5-hydroxytryptophan Pharmacol Biochem Behav 7 1977 515 518
34. W.F. Byerley, L.L. Judd, F.W. Reimherr, and B.I. Grosser 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects J Clin Psychopharmacol 7 1987 127 137
35. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. The Cochrane Library, vol. 3. 2/26/2003; 2003
36. A. Khan, S.R. Khan, G. Walens, R. Kolts, and E.L. Giller Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports Neuropsychopharmacology 28 Mar 2003 552 557
37. R. Temple, and S.S. Ellenberg Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues Ann Intern Med 133 Sep 19 2000 455 463
38. M.C. Boadle-Biber Regulation of serotonin synthesis Prog Biophys Mol Biol 60 1993 1 15
39. H.J. Gijsman, J.M. van Gerven, and M.L. de Kam Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers J Clin Psychopharmacol 22 2002 183 189
40. K. Zmilacher, R. Battegay, and M. Gastpar l-5-Hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression Neuropsychobiology 20 1988 28 35
41. N. Matussek, J. Angst, and O. Benkert The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients Adv Biochem Psychopharmacol 11 1974 399 404
42. Food and Drug Administration. Impurities confirmed in dietary supplement 5-hydroxy-l-tryptophan, 〈http://vm.cfsan.fda.gov/∼lrd/tp5htp.html〉 August 31, 1998 [Accessed 15:12:2004]
43. D. Michelson, S.W. Page, and R. Casey An eosinophilia-myalgia syndrome related disorder associated with exposure to l-5-hydroxytryptophan J Rheumatol 21 1994 2261 2265
44. B.L. Williamson, K. Klarskov, A.J. Tomlinson, G.J. Gleich, and S. Naylor Problems with over-the-counter 5-hydroxy-l-tryptophan Nat Med 4 1998 983
45. Y.T. Das, M. Bagchi, D. Bagchi, and H.G. Preuss Safety of 5-hydroxy-l-tryptophan Toxicol Lett 150 Apr 15 2004 111 122
46. R. Lane, and D. Baldwin Selective serotonin reuptake inhibitor-induced serotonin syndrome: review J Clin Psychopharmacol 17 Jun 1997 208 221
47. H. Sternbach The serotonin syndrome Am J Psychiat 148 1991 705 713
48. K.C. Mills Serotonin syndrome Am Fam Physician 52 Oct 1995 1475 1482
49. S.M. Gwaltney-Brant, J.C. Albretsen, and S.A. Khan 5-Hydroxytryptophan toxicosis in dogs: 21 cases (1989-1999) J Am Vet Med Assoc 216 2000 1937 1940
50. H. Meltzer, B. Bastani, K. Jayathilake, and M. Maes Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder Neuropsychopharmacology 17 1997 1 11
51. M. Nardini, R. De Stefano, M. Iannuccelli, R. Borghesi, and N. Battistini Treatment of depression with l-5-hydroxytryptophan combined with chlorimipramine, a double-blind study Int J Clin Pharmacol Res 3 1983 239 250
52. N. Kline, and W. Sacks Treatment of depression with an MAO inhibitor followed by 5-HTP - an unfinished research project Acta Psychiatr Scand Suppl 280 1980 233 241
53. J.J. Alino, J.L. Gutierrez, and M.L. Iglesias 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study Int Pharmacopsychiat 11 1976 8 15
54. M. Nicolodi, and F. Sicuteri Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy Adv Exp Med Biol 398 1996 373 379
55. H. Quadbeck, E. Lehmann, and J. Tegeler Comparison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine Neuropsychobiology 11 1984 111 115